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Abstract Type II collagen is the major protein of cartilage and
is synthesized as a procollagen in two forms (IIA and IIB),
generated by di¡erential splicing of the gene primary transcript.
Previous studies have indicated that only type IIB is expressed
in di¡erentiated chondrocytes. Here, we examined the e¡ects of
bone morphogenetic protein (BMP)-2 and transforming growth
factor (TGF)-L1 on the expression of IIA and IIB forms ex-
pressed in de-di¡erentiated chondrocytes grown in monolayer.
Our results demonstrate that BMP-2 favors expression of type
IIB whereas TGF-L1 potentiates expression of type IIA induced
by subculture. These observations reveal the speci¢c capability
of BMP-2 to reverse the de-di¡erentiation state of chondro-
cytes.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cartilage development is an early morphogenetic step in
skeletogenesis. This process involves the commitment, conden-
sation and di¡erentiation of mesenchymal cells into chondro-
cytes which ultimately leads to the synthesis and secretion of
proteins characteristic of the cartilage matrix, such as type II,
IX and XI collagens, and the large proteoglycan aggrecan [1].
Type II collagen is the major component of the cartilage col-
lagen ¢brils and is classically considered a reference marker
for the di¡erentiated chondrocyte phenotype. This protein is a
homotrimer of three K1(II) chains, which are products of one
gene (Col2a1). Two forms of type II collagen are generated by
alternative RNA splicing [2]. The type IIA form includes and
the type IIB form excludes a 69 amino acid cysteine-rich (CR)
domain encoded by exon 2 in the NH2-propeptide. CR do-
mains are present in a variety of other extracellular proteins
including ¢brillar type I, III and V procollagens, chordin in
Xenopus [3], and the chordin homologue sog in Drosophila [4].
Recent studies indicate that CR domains could provide bind-
ing modules for diverse transforming growth factor (TGF)-L
superfamily members, such as bone morphogenetic proteins
(BMPs). Zhu et al. [5] showed that the NH2-propeptide con-
taining the CR domain of type IIA procollagen binds to
BMP-2 and TGF-L1, two regulators of various developmental
processes as well as chondrogenesis. This ¢nding led to the
hypothesis that type IIA procollagen could play a broader
role than a purely structural one, by controlling in the extra-
cellular space the amount of speci¢c morphogenetic agents [5].
In support of this hypothesis, procollagen IIA mRNA, like
chordin mRNA, showed dorsalizing activity in Xenopus em-
bryo microinjection assays and the CR domain was required
for this anti-BMP activity [6].
In supplement of the developmental standpoint mentioned
above, it is of particular interest to note that type IIA pro-
collagen is expressed in pre-chondrocytes, mesenchymal and
epithelial cells, and in a number of embryonic, non-chondro-
genic tissues such as somites and intervertebral disks, whereas
type IIB procollagen is expressed in di¡erentiating and adult
cartilage and in adult tissues such as sclera [7^14]. Thus, in
regard of cartilage biology, the shift from type IIA to type IIB
is a sign of chondrocyte di¡erentiation. On the other hand, re-
expression of type IIA procollagen has been reported in hu-
man osteoarthritic cartilage and this could represent a poten-
tial reversion towards a chondroprogenitor cellular phenotype
[15].
Therefore, it is important to examine the spliced forms of
type II procollagen mRNA expressed by the chondrocyte for
an accurate determination of its phenotype in an in vivo or in
vitro situation. In this latter case, several studies that moni-
tored the stability of the chondrocyte phenotype have shown
that culture of these cells in monolayers on plastic substrata
for a long time or upon repeated passages leads to the loss of
their spherical shape and to the acquisition of a ¢broblastic
morphology. These shape changes are linked to biochemical
changes, including the progressive reduction of type II colla-
gen synthesis and other cartilage-characteristic proteins [16^
25], a process designated ‘de-di¡erentiation’.
Only a few studies have been performed to understand the
molecular mechanisms underlying chondrocyte de-di¡erentia-
tion. The transcription factors SP1 and SP3 and their ratio
control the expression of the Col2a1 promoter during chon-
drocyte de-di¡erentiation [26,27]. Since de-di¡erentiation of
chondrocytes represents a limiting factor in mass cell produc-
tion required for the treatment of articular cartilage defects
[28], further analysis is needed to better de¢ne how cartilage-
speci¢c genes are modulated in monolayer culture, to ulti-
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mately prevent de-di¡erentiation or promote re-di¡erentiation
of chondrocytes. In this context, growth factors are good
candidates to in£uence the transcriptional machinery of the
chondrocytes. In particular, the BMPs promote chondrogenic
and osteogenic phenotypes in vitro [29^31]. Recently, we
showed that BMP-2 stimulates type II collagen expression
and synthesis in mouse chondrocytes and TGF-L signaling
antagonizes this e¡ect [32,33]. This observation prompted us
to investigate the role of BMP-2 and TGF-L1 in the regula-
tion of de- and re-di¡erentiation of mouse chondrocytes in
monolayer culture, with particular attention given to the ex-
pression of spliced forms of type II procollagen mRNA.
2. Materials and methods
2.1. Cell culture
Embryonic mouse chondrocytes were isolated from the ventral
parts of the rib cages of 17.5 dpc mice, as described [34]. These
chondrocytes were seeded on 90 mm Corning dishes with 1U106
cells/dish and cells at this stage were designated P0. Chondrocytes
were cultured with 1:1 high-glucose Dulbecco’s modi¢ed Eagle’s me-
dium/Ham F12 containing 10% fetal bovine serum (FBS) and supple-
mented with 2 mM L-glutamine, 100 U/ml penicillin, 100 Wg/ml strep-
tomycin (all products from Invitrogen), at 37‡C in 5% CO2. Con£uent
cells were detached using 0.05% trypsin^EDTA and seeded onto 90
mm Corning dishes for ampli¢cation. The progressive loss of the
di¡erentiated phenotype was achieved by serial subcultures, up to
six passages (cells were then designated P1^P6). P1 and P6 chondro-
cytes were seeded in 6 well culture dishes with 1.5U105 cells/well and
grown for 3 or 6 days in medium containing 1% FBS supplemented
with BMP-2 (0^100 ng/ml) or TGF-L1 (0^5 ng/ml). Recombinant
human BMP-2 was produced and puri¢ed by Wyeth Research (Cam-
bridge, MA, USA). Recombinant human TGF-L1 was purchased
from Sigma. The culture medium was replaced every day. In experi-
ments dedicated to the Western blotting analysis of type II procolla-
gen synthesized by P1 chondrocytes, 20 Wg/ml ascorbic acid (Sigma)
was added daily to the culture medium.
2.2. Immuno£uorescence
P0 and P1 chondrocytes were seeded on glass coverslips in 6 well
culture dishes with 4U105 cells/well (P0) or 1.5U105 cells/well (P1).
P0 chondrocytes were grown for 24 h and P1 chondrocytes were
grown for 3 and 6 days, in the presence of 1% FBS supplemented
or not with 100 ng/ml BMP-2 or 5 ng/ml TGF-L1. The cell cultures
were then treated as previously described [33], followed by an incu-
bation for 1 h with the 2B1 monoclonal antibody recognizing an
epitope located in the triple helix of type II collagen [35], or with
polyclonal rabbit antibodies raised against mouse type I collagen
(Novotec ref. 20151) [36]. Cells were then washed with phosphate-
bu¡ered saline (PBS) and incubated for 1 h with Cy3- or Cy2-con-
jugated anti-mouse or anti-rabbit secondary antibodies (Jackson) in
PBS containing 0.25 Wg/ml Hoechst 33258 (Sigma) to visualize nuclei.
Chondrocytes were again washed with PBS and coverslips were
mounted in glycerol/PBS (1:1) for their observation by epi£uorescence
with a Zeiss Axioplan 2 microscope equipped with a CoolSNAP Fx
camera (Roper Scienti¢c). Image acquisition and overlay were
achieved with Metaview software.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNAs were extracted and reverse-transcribed as previously
described [33]. RT-PCR with glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) primers was performed to ascertain that an equivalent
amount of cDNA was synthesized from the di¡erent samples. The
conditions for the PCR ampli¢cations and the sequences of the prim-
ers for GAPDH and type IIA/IIB procollagen have been previously
reported [32,33]. The total amount of type II procollagen (IIA+IIB)
transcripts was determined by designing a sense oligonucleotide (5P-
GGTTTGGAGAGACCATGAAC-3P) in exon 50 and an antisense
primer (5P-TGGGTTCGCAATGGATTGTG-3P) in exon 52 of the
mouse Col2a1 gene, from a sequence available in GenBank
(M65161). Samples were ampli¢ed for 20 cycles, with denaturation
at 95‡C (30 s), annealing at 55‡C (30 s), and extension at 72‡C
(30 s), giving a product size of 463 bp. The RT-PCR products were
separated by electrophoresis on 2% agarose gels and stained with
ethidium bromide. Amplicons of the expected size were obtained,
cloned in a pCR2.1-TOPO vector (Invitrogen, San Diego, CA,
USA) and sequenced (Genome Express, France) to con¢rm the iden-
tity of the sequences. Photographs of gels of RT-PCR experiments
using cells obtained from three independent dissections were analyzed
with Image Quant software (Amersham Biosciences).
2.4. Western blot analysis
Cells were washed three times with PBS and scraped into 100 Wl of
Laemmli sample bu¡er. After boiling for 5 min in the presence of
2-mercaptoethanol, the proteins were separated on 6% polyacrylamide
gels and transferred to polyvinylidene di£uoride membranes (Milli-
pore). Non-speci¢c binding sites were blocked by incubating the mem-
brane overnight at 4‡C in 0.2% (w/v) non-fat dry milk blocker (Bio-
Rad) dissolved in TBS (20 mM Tris^HCl, 0.5 M NaCl, pH 7.5). After
rinsing with TBS-T (TBS containing 0.1% Tween 20), the membrane
was incubated for 2 h with polyclonal rabbit antibodies raised against
mouse type II collagen (Novotec, ref. 20251) [36], at 2.5 Wg/ml in TBS-
T, 0.2% blocker. The membrane was washed with TBS-T and incu-
bated for 1 h with goat alkaline phosphatase-conjugated anti-rabbit
IgG (Bio-Rad). After multiple washes in TBS-T, bound antibodies
were detected on X-ray ¢lms using a Bio-Rad Immun-star chemilu-
minescent substrate. Either Ponceau S staining of immunoblots or
parallel Coomassie brilliant blue-stained gels con¢rmed equivalent
protein loading.
3. Results and discussion
When chondrocytes were isolated from mouse embryos and
seeded for 24 h at subcon£uence, they presented round and
polygonal shapes and were all positively stained by immuno-
£uorescence for type II collagen, attesting the purity of the
chondrogenic population (Fig. 1A). The gene expression of
Fig. 1. A: Morphology and staining of P0 chondrocytes seeded for
24 h. B: RT-PCR analysis of expression of type II procollagen in
P0 chondrocytes seeded for 24 h, and in P1 chondrocytes grown for
3 and 6 days after their ¢rst passage.
FEBS 27313 3-6-03 Cyaan Magenta Geel Zwart
U. Valcourt et al./FEBS Letters 545 (2003) 115^119116
total type II procollagen decreased gradually with time from
P0 to P1, illustrating the de-di¡erentiation process classically
observed for chondrocytes maintained in monolayer culture
on plastic (Fig. 1B). More precisely, the type IIB form of type
II procollagen mRNA was the only form expressed by P0
chondrocytes, as expected from di¡erentiated chondrocytes,
whereas the type IIA form was expressed only after subcul-
ture, in P1 chondrocytes (Fig. 1B). Recently, Kim et al. [37]
showed that alternative splicing of type II procollagen pre-
mRNA occurs during de-di¡erentiation of rat chondrocytes
in monolayer, but both type IIA and type IIB transcripts were
already expressed in chondrocytes on the day of their isola-
tion. This discrepancy between their results and ours could be
explained by species di¡erences, since we previously showed
Fig. 2. A: Phase contrast microscopy and staining of P1 chondrocytes grown for 3 and 6 days in the presence of 1% FBS alone (0) or supple-
mented with 100 ng/ml BMP-2 or 5 ng/ml TGF-L1, as indicated. At the top, control cells (0) show spread or ¢broblastic morphology whereas
BMP-2-treated cells are organized in refractile clusters. TGF-L1-treated cells show £attened or ¢broblastic morphology. In the middle and at
the bottom, cells are double-stained for type II collagen with Cy3-conjugated secondary antibodies (red) and for type I collagen with Cy2-con-
jugated secondary antibodies (green). Nuclei are stained with Hoechst dye (blue). B: Western blotting analysis of type II procollagen accumula-
tion in P1 chondrocyte monolayers. Cells were grown for 3 and 6 days in the presence of 1% FBS (0) or in the presence of 1% FBS supple-
mented with BMP-2 or TGF-L1, at the indicated concentrations. The positions of globular molecular size markers are shown on the right.
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that type IIB mRNA is the only spliced variant expressed in
mouse rib cage [33].
We further investigated the responsiveness of de-di¡erenti-
ated P1 chondrocytes to BMP-2 and TGF-L1, during a 3 and
6 day culture period. Cells treated with BMP-2 showed polyg-
onal and round shapes and were organized in refractile clus-
ters, a trait of di¡erentiated chondrocytes (Fig. 2A). In con-
trast, control chondrocytes grown in the presence of 1% serum
showed a spread or ¢broblastic morphology and TGF-L1
treatment accentuated this e¡ect. The addition of BMP-2 in-
creased the number of cells positively stained for type II col-
lagen on days 3 and 6, as compared to untreated cells (Fig.
2A). It should be noted that the positive staining for type II
collagen observed after BMP-2 treatment was mainly localized
in cells organized in clusters. Inversely, TGF-L1 suppressed
type II collagen-positive staining (Fig. 2A). Concomitantly,
some cells were positively stained for type I collagen in the
control and BMP-2-treated cultures while most cells were pos-
itive for type I collagen in the presence of TGF-L1, whatever
the time in culture (Fig. 2A). Type I collagen has been pre-
viously described as a marker of de-di¡erentiated chondro-
cytes [16]. Thus, our data together indicate that (i) embryonic
mouse chondrocytes undergo de-di¡erentiation after subcul-
ture and (ii) TGF-L1 potentiates this de-di¡erentiation process
whereas BMP-2 reverses it. We further evaluated this di¡er-
ential responsiveness by a Western blotting analysis of the
amount of type II procollagen present in cell monolayers.
Our results showed that BMP-2, but not TGF-L1, favors
type II procollagen accumulation in P1 chondrocyte mono-
layers in a time- and dose-dependent manner (Fig. 2B).
Subsequently, we investigated whether alternative splicing
of type II procollagen pre-mRNA in de-di¡erentiated chon-
drocytes was modulated by BMP-2 or TGF-L1 treatment. In-
deed, RT-PCR analyses of P1 chondrocytes indicated that
BMP-2 favors the expression of type IIB transcript whereas
TGF-L1 favors the expression of type IIA transcript (Fig.
3A,B). The e¡ect of each growth factor on the ratio of ex-
pression of the two transcripts was signi¢cant, as shown after
densitometric analysis (Fig. 3C). Furthermore, when the ef-
fects of BMP-2 were evaluated on late de-di¡erentiated chon-
drocytes (P6), we found again that BMP-2 was able to stim-
ulate Col2a1 expression, particularly that of type IIB
transcript (Fig. 4).
Thus, this study shows for the ¢rst time that BMP-2
and TGF-L1 have speci¢c, opposite e¡ects on the alternative
splicing of type II procollagen pre-mRNA. In regard of this
splicing, BMP-2 reverses the program of chondrocyte de-
di¡erentiation, as attested by re-expression of the cartilage-
characteristic type IIB procollagen. This important feature
needs to be considered during the cell ampli¢cation procedure
for the currently used autologous chondrocyte transplanta-
tion, even though other skeletal markers need to be evaluated,
as well as the ability of human articular chondrocytes to re-
Fig. 3. A,B: RT-PCR analysis of type IIA and type IIB procollagen
spliced forms in P1 chondrocytes grown for 3 and 6 days in the
presence of 1% FBS alone (0) or supplemented with BMP-2 or
TGF-L1, at the indicated concentrations. C: Densitometric quantita-
tion of the type IIA/IIB ratio, shown relative to the level of control
cells grown in the presence of 1% FBS alone (1.00), at the indicated
days. Values given are the arithmetic means, and the error bars rep-
resent standard deviations of three independent experiments.
Fig. 4. RT-PCR analysis of type II procollagen in P6 chondrocytes
grown for 3 days in the presence of 1% FBS alone (0) or supple-
mented with 50 or 100 ng/ml BMP-2, as indicated.
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spond to BMP-2. In addition, we have established a novel
cellular model to study the role of the Col2a1 exon 2-encoded
peptide and to decipher the molecular mechanisms underlying
alternative splicing of type II procollagen pre-mRNA. Such
studies should contribute to gain insight into the regulation of
the chondrocyte phenotype and represent a ¢rst step to fur-
ther control this phenotype in vitro.
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